Kiniksa Pharmaceuticals Raises 2026 Revenue Guidance to Over $1 Billion
Kiniksa Pharmaceuticals (KNSA) has officially raised its full-year revenue guidance for 2026, now projecting earnings between $1.045 billion and $1.050 billion. CEO Sanj Patel attributed this upward revision to robust ongoing performance within the company's current portfolio. Looking toward long-term growth catalysts, the company expects to release data for its KPL-387 candidate in the second half of 2027. This upcoming clinical milestone is a key component of the company's future pipeline strategy and market expansion plans.
Tickers: $KNSA
Topics: earnings call financial outlook revenue guidance
Read the full article at Seeking Alpha
Part of the story Equinix Reports Strong Q3 2026 Results and Raises Full-Year Guidance (49 articles)